DPX rPA
Alternative Names: DPX-rPALatest Information Update: 20 Jan 2025
Price :
$50 *
At a glance
- Originator BioVaxys
- Developer BioVaxys; National Institutes of Health
- Class Anthrax vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Anthrax